Yahoo! Finance: PFE News

Latest Financial News for PFIZER INC

• Final Glance: Pharmaceuticals companies (AP)

  (Thu, 4 Dec 2008 22:59:26 Etc/GMT)

• 4 Reasons to Choose Funds Over Stocks (at Motley Fool)

  (Thu, 4 Dec 2008 20:13:32 Etc/GMT)

• Pfizer Blows Statin Smoke (at Motley Fool)

  (Thu, 4 Dec 2008 19:55:26 Etc/GMT)

• Poor Pozen (at Motley Fool)

  (Thu, 4 Dec 2008 18:56:29 Etc/GMT)

• Drug Deals Require Cash (at Motley Fool)

  (Thu, 4 Dec 2008 18:36:33 Etc/GMT)

• Midday Glance: Pharmaceuticals companies (AP)

  (Thu, 4 Dec 2008 18:12:52 Etc/GMT)

• UPDATE - MannKind Phase 3 inhaled insulin studies meet goal (at Reuters)

  (Thu, 4 Dec 2008 17:34:02 Etc/GMT)

• One More Step For MannKind (at Investopedia)

  (Thu, 4 Dec 2008 17:22:38 Etc/GMT)

• Early Glance: Pharmaceuticals companies (AP)

  (Thu, 4 Dec 2008 15:47:20 Etc/GMT)

• Cramer's Mad Money - Will Pfizer Buy Allergan? (12/3/08) (at Seeking Alpha)

  (Thu, 4 Dec 2008 09:49:29 Etc/GMT)

Yahoo! Finance: PFE Financial Blogs

Latest Financial Financial Blogs for PFIZER INC

• Cramer's Mad Money - Will Pfizer Buy Allergan? (12/3/08) (at Seeking Alpha)

  (Thu, 4 Dec 2008 09:49:29 Etc/GMT)

• Surprise, Pfizer Study Says Lipitor Beats Generic Zocor (at Seeking Alpha)

  (Wed, 3 Dec 2008 17:03:50 Etc/GMT)

• Poor Strategy Is Costly (at Seeking Alpha)

  (Wed, 3 Dec 2008 11:56:38 Etc/GMT)

• Short Interests in Pfizer and Dendreon Decline - Is Bearish Sentiment Dissipating? (at Seeking Alpha)

  (Wed, 3 Dec 2008 08:14:51 Etc/GMT)

• Will Merck's Atherosclerosis Drug Fare Better Than Pfizer's Did? (at Seeking Alpha)

  (Wed, 3 Dec 2008 06:41:37 Etc/GMT)

• Yes, We Are in a Recession (Zacks.com)

  (Mon, 1 Dec 2008 21:19:51 Etc/GMT)

  I hate to say I told you so, but I told you so. Here are a few quotes from the Zacks Strategy Report of January 2008.

• Latest Postmortem on Torcetrapib Leaves Hope for HDL Boosters (at The Wall Street Journal Online)

  (Mon, 1 Dec 2008 12:04:00 Etc/GMT)

• From Patent Thickets to Payoffs: How Big Pharma Fights Generics (at The Wall Street Journal Online)

  (Fri, 28 Nov 2008 14:01:00 Etc/GMT)

• Thanksgiving Economic Data: Mostly Turkeys (at Seeking Alpha)

  (Thu, 27 Nov 2008 09:43:37 Etc/GMT)

• Johnson & Johnson Is the Latest FDA Casualty (at Seeking Alpha)

  (Thu, 27 Nov 2008 08:00:44 Etc/GMT)

MSN Money News - PFE

News about Pfizer Inc

• Pfizer Blows Statin Smoke

  (Thursday, December 04, 2008 1:13 PM)

  It presents some mildly persuasive numbers to try to win back customers for Lipitor.

• Cramer: No More Dow at 7350

  (Thursday, December 04, 2008 12:30 PM)

  Jim says look at the bright side. There are not that many swing players left in the Dow that can bring it back down to its painfully low levels.

• Poor Pozen

  (Thursday, December 04, 2008 12:12 PM)

  Good data, but will the FDA agree?

• Early Glance: Pharmaceuticals companies

  (Thursday, December 04, 2008 10:47 AM)

  NEW YORK (AP) - Shares of some top pharmaceuticals companies are down at 10 a.m.:

• Final Glance: Pharmaceuticals companies

  (Wednesday, December 03, 2008 5:55 PM)

  NEW YORK (AP) - Shares of some top pharmaceuticals companies were up at the close of trading:

• Patients Taking Lipitor Had a Significantly Reduc

  (Wednesday, December 03, 2008 8:18 AM)

  Pfizer announced the results of an observational study that showed patients taking Lipitor® (atorvastatin calcium) had a significant 13 percent reduction in the relative risk of experiencing a

• ($) High Time for a Merger Wave

  (Tuesday, December 02, 2008 4:00 PM)

  Companies with cash stockpiles are sitting on huge opportunities to add value.

PFE - News and Analysis from Seeking Alpha

'PFE' Tag RSS Syndication from SeekingAlpha.com

• Fast Money Recap - Is Pharma Healthy? (12/3/08)

  (Thu, 04 Dec 2008 08:04:06 -0500)

  Fast Money Recap, Wednesday December 3.

  Coke (KO), Cisco Systems (CSCO), Biotechnology Index (BTK), Freeport McMoRan (FCX), Biotechnology Index (BTK), US Gyp (USG), Philip Morris (PM), Altria (MO)

  
  Complete Story »

• Cramer's Mad Money - Will Pfizer Buy Allergan? (12/3/08)

  (Thu, 04 Dec 2008 04:49:29 -0500)

  Stocks discussed in the in-depth session of Jim Cramer’s Mad Money TV program, Wednesday, December 3.

  The Plaxico Burress Good Judgment Award

  The Fed is finally getting it right in solving the housing crisis and is buying mortgage-backed paper. As a result, mortgage rates are dropping, homeowners can refinance and new buyers are appearing. Cramer is outraged that Bernanke didn’t implement this plan a year ago, since such an action would have spared the economy a lot of pain. He therefore gives Ben Bernanke the Plaxico Burress Award for Good Judgment.

  
  Complete Story »

• Surprise, Pfizer Study Says Lipitor Beats Generic Zocor

  (Wed, 03 Dec 2008 12:03:50 -0500)

  Mike Huckman submits:

  CNBC.com

  Tuesday afternoon the "Journal of the American Medical Association" ((JAMA)) published a study showing that cheaper, generic heart drugs work just as well as more expensive, brand-name heart drugs.

  
  Complete Story »

• Poor Strategy Is Costly

  (Wed, 03 Dec 2008 06:56:38 -0500)

  John Singer submits:

  Across industries, governments and institutional settings, there is widespread error confusing tactics with strategy.Strategy is the relationship between means and objectives.It answers three questions:

  1. Where do we go?
  2. How do we get there?
  3. How much will it cost?

  It is an inherently creative process, shaped as a vision interacts with its operating environment.Strategy design is roughly similar to Michelangelo’s approach to sculpture: he understood his task as finding the form hidden in the block of marble.

  
  Complete Story »

• More Focused Defensive Index

  (Wed, 03 Dec 2008 03:24:54 -0500)

  Mike Havrilla submits:

  

  The accompanying table includes an updated version of the ETF Innovators ((ETFI)) ETFI Highly Defensive PerformIdex of 36 companies based in the U.S., Canada, and Europe with market caps over $10B, which are the leaders by market cap in their defensive industry groups. This update includes a 10% reduction in the number of companies with an equal distribution of 12 each from consumer staples and healthcare, with the remaining 12 companies chosen from a variety of defensive industry groups.

  
  Complete Story »

• Short Interests in Pfizer and Dendreon Decline - Is Bearish Sentiment Dissipating?

  (Wed, 03 Dec 2008 03:14:51 -0500)

  Mike Huckman submits:

  I know that simply pointing this out will draw the ire of certain Pfizer (PFE) investors who happen to read my blog, but the fact is that PFE is the only major pharmaceutical company whose short interest is big enough to crack the Barron's Top-40.

  PFE comes in at #20 with 56,385,734 shares sold short as of November 14th. But the short position in the stock shrank by 12,000,000 from Halloween to the middle of last month. That decline ranks as the seventh-biggest among stocks listed on the New York Stock Exchange. CNBC's parent company, General Electric...

• Will Merck's Atherosclerosis Drug Fare Better Than Pfizer's Did?

  (Wed, 03 Dec 2008 01:41:37 -0500)

  Derek Lowe submits:

  Ever since the catastrophic failure of Pfizer's (PFE) HDL-raising CETP inhibitor torcetrapib in late 2006, everyone involved has wondered just what the problem was. There was a definitely higher cardiovascular-linked death rate in the drug-treatment group as opposed to placebo - which led to the screeching halt in Phase III, as well it might - but why? Is there something unexpectedly bad about raising HDL? Or just in raising it by inhibiting the CETP enzyme, which might well provide a different lipoprotein profile than...

• Dividend Aristocrats Outperform in November

  (Mon, 01 Dec 2008 05:47:52 -0500)

  David I. Templeton submits:

  A preliminary review of the year to date performance of S&P's Dividend Aristocrats shows they are outperforming the major U.S. domestic indexes. Through the first eleven months of 2008, the Aristocrats have generated a capitalization weighted return of -22.4% versus a -39.0% return for the S&P 500 Index. The return for the Dow Jones Industrial Average and the NASDAQ composite index is -33.4% and -42.1%, respectively.
  
  The spreadsheet below details performance information for each of the Aristocrats. It should be noted the Anheuser-Busch was removed from the S&P 500 Index as of November 18 due to...

• Thanksgiving Economic Data: Mostly Turkeys

  (Thu, 27 Nov 2008 09:43:37 -0500)

  Zacks.com submits:

  By Dirk van Dijk

  Yesterday we got a tsunami of new economic data, and in honor of Thanksgiving, most of the numbers were turkeys. Starting with the least-bad numbers:

  
  Complete Story »

• Johnson & Johnson Is the Latest FDA Casualty

  (Thu, 27 Nov 2008 03:00:44 -0500)

  Mike Huckman submits:

  Does the Food and Drug Administration approve drugs anymore? Or are we seeing the lame-duck leadership at the agency punt any action over to the next administration?

  Late Tuesday, the FDA gave Pfizer (PFE) full, formal approval of its new HIV/AIDS drug. But that was only to be followed by news out of Dow component Johnson & Johnson (JNJ) Wednesday morning that the agency can't approve JNJ's new drug for hospital-acquired infections just yet. In early trading, JNJ was the biggest dollar and percentage loser in the sector.

  
  Complete Story »

Investor Clicks Financial Advertising

News for Pfizer Inc. - Google Finance

News for Pfizer Inc. - Google Finance

• Pfizer Blows Statin Smoke

  (Thu, 04 Dec 2008 20:57:33 GMT)
  Pfizer Blows Statin Smoke
  Motley Fool - 3 hours ago

  By Brian Orelli Over the past couple of years, Pfizer (NYSE: PFE) has been getting a small preview of what it's going to feel like when Lipitor, which fights high cholesterol, goes off patent in ...

• Pfizer May Have Fresh Wave of Firings as Generic Threat Looms

  (Thu, 04 Dec 2008 19:23:55 GMT)
  Pfizer May Have Fresh Wave of Firings as Generic Threat Looms
  Bloomberg - 4 hours ago

  By Shannon Pettypiece Dec. 4 (Bloomberg) -- Pfizer Inc., the world?s biggest drugmaker, may announce new job cuts by the end of next month as it works to curb spending before cheaper copies of its ...

• BridgewaterEquity.com Free Fundamental Sector & Market Research on NLY, PCS, PFE and XOM

  (Thu, 04 Dec 2008 17:28:09 GMT)
  BridgewaterEquity.com Free Fundamental Sector & Market Research on NLY, PCS, PFE and XOM
  Market Wire (press release) - 6 hours ago

  NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Bridgewater Equity (BWE). LONDON--(Marketwire - December 4, 2008) - BridgewaterEquity.com inspires to bring the best from ...

  BridgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on NLY, PCS, PFE and XOM - istockAnalyst.com (press release)
  

• One More Step For MannKind (MNKD, PFE, LLY, NVO)

  (Thu, 04 Dec 2008 17:26:31 GMT)
  One More Step For MannKind (MNKD, PFE, LLY, NVO)
  Investopedia - 6 hours ago

  Do you remember the "Underpants Gnomes" episode of South Park ? More to the point, do you remember their three-step business plan? It went a little something like this: That, in a nutshell, is the ...

  UPDATE 3-MannKind Phase 3 inhaled insulin studies meet goal - Trading Markets (press release)
  

• Malcolm Berko -- Easy to swallow stocks

  (Thu, 04 Dec 2008 17:15:20 GMT)
  Malcolm Berko -- Easy to swallow stocks
  Kankakee Daily Journal - 7 hours ago

  Dear Mr. Berko: I would like to buy some drug company stocks. Do you still like Pfizer, which you recommended some months ago at $18? What is your opinion of Bristol-Myers Squibb? The shares are ...

• MPI close to buying Pfizer buildings

  (Thu, 04 Dec 2008 15:52:49 GMT)
  MPI close to buying Pfizer buildings
  Kalamazoo Gazette - MLive.com - 8 hours ago

  KALAMAZOO -- MPI Research and Pfizer Inc. are in the final stages of closing a deal that will allow MPI to buy two of Pfizer's downtown Kalamazoo research laboratories for $1 each. Pfizer ...

• Pfizer: Study finds Lipitor cuts heart-attack risk

  (Thu, 04 Dec 2008 11:07:05 GMT)
  Pfizer: Study finds Lipitor cuts heart-attack risk
  TheDay - 13 hours ago

  By Lee Howard Pfizer Inc. announced Wednesday the results of a study that appear to show its cholesterol drug Lipitor improves chances of avoiding a heart attack when compared to the Merck & Co ...

• Pfizer's chief medical officer to retire

  (Thu, 04 Dec 2008 11:06:51 GMT)
  Pfizer's chief medical officer to retire
  TheDay - 13 hours ago

  By Lee Howard Joe Feczko, Pfizer Inc.'s chief medical officer who experienced the highs of introducing blockbuster new drugs and the lows of helping pull the plug on failures, has announced his ...

• Sanofi-Aventis Joins Glaxo, Pfizer in Cutting US Sales Jobs

  (Thu, 04 Dec 2008 10:54:09 GMT)
  Sanofi-Aventis Joins Glaxo, Pfizer in Cutting US Sales Jobs
  Bloomberg - 13 hours ago

  By Trista Kelley Dec. 4 (Bloomberg) -- Sanofi-Aventis SA, the French drugmaker that replaced its chief executive this week, is paring US sales positions, echoing moves by rivals to respond to a ...

• Cramer Says Pfizer (PFE) Should Buy Allergan (AGN)

  (Wed, 03 Dec 2008 23:23:54 GMT)
  Cramer Says Pfizer (PFE) Should Buy Allergan (AGN)
  StreetInsider.com (subscription) - Dec 3, 2008

  On Mad Money tonight, Jim Cramer said Pfizer (NYSE: PFE) should really take a strong look at buying Allergan (NYSE: AGN). Cramer thinks this is a smart play similar to Johnson & Johnson buying out ...

MarketWatch.com - All MarketWatch News - PFE

MarketWatch, a leading publisher of business and financial news, offers users up-to-the minute news, investment tools, and subscription products.

• Audio: Sandler: Everything is attractively valued, so don't be stupid!

  (Tue, 25 Nov 2008 12:19:42 -0500)

  In December we're going to see a flight to junk, the lousiest companies people don't even like as they chase performance. Don't follow them! So says Doug Sandler, chief equity officer at Riverfront Investment Group. Sandler tells Andrew O'Day the market as a whole is so beaten up now, long term investors eventually can make tremendous returns with quality companies. He recommends health care, consumer staples and software; and warns to stay clear from financials, home builders, automakers, and retailers.

• As diabetes surges, the search for better treatments intensifies

  (Tue, 25 Nov 2008 16:33:00 -0500)

  By the time Dana Metzger started college, she wanted an alternative to the daily insulin shots she'd been taking for 10 years. Diagnosed with Type 1 diabetes at age 9, Metzger spent her life experimenting with different regimens before finding the insulin pump, a treatment that fit her busy lifestyle.

• Audio: Stovall: December will lay groundwork for 2009 rally

  (Tue, 25 Nov 2008 15:51:55 -0500)

  Sam Stovall, the chief investment strategist at Standard & Poor's Equity Research, has a long December wish list that boils down to one point: He needs to see the economic "decline is losing speed rather than gaining speed." Stovall thinks moves by the incoming president, a Fed rate cut and signs that housing falloff is abating would help there. None of these would help stocks much in December, but would lay the groundwork for 20% gains in 2009, says Stovall.

• Audio: Midday report from MarketWatch Radio Network

  (Thu, 20 Nov 2008 12:27:39 -0500)

  The latest money news from anchor Diane Brown.

• Before the Bell: Citigroup, Pfizer, General Electric in the spotlight

  (Thu, 20 Nov 2008 08:46:00 -0500)

  U.S. stock market futures dropped Thursday as fears over the financial and automotive sectors continued and jobless figures showed another sharp rise.

• Pfizer pulls E.U. application to sell Viagra over the counter

  (Thu, 20 Nov 2008 07:46:00 -0500)

  Pfizer on Thursday said it withdrew an application to sell Viagra without a prescription in Europe after regulators fretted about the safety implications.

• Pfizer pulls E.U. app to sell Viagra without prescription

  (Thu, 20 Nov 2008 05:37:34 -0500)

  LONDON (MarketWatch) -- Pfizer said it's withdrawn an application to sell Viagra without a prescription in Europe. Pfizer said that it has decided to withdraw the application in order to fully consider comments from the European Medicines Agency's Committee for Medicinal Products for Human Use, recognizing that there were some concerns regarding the proposed supply of Viagra 50 miligram tablets without a prescription in the European Union.

• Pfizer pulls E.U. app to sell Viagra without prescription

  (Thu, 20 Nov 2008 05:35:17 -0500)

• Movers & Shakers: Thursday's biggest gaining and declining stocks

  (Thu, 20 Nov 2008 17:31:00 -0500)

  Among the companies whose shares are seeing active trade in Thursday’s session are Ambac, Citigroup, Ford and General Motors.

• Big company boards' get 11% raises in '08 to $2 mln: report

  (Wed, 19 Nov 2008 13:39:46 -0500)

  NEW YORK (MarketWatch) -- Board directors for companies in the Standard & Poor's 500 index gave themselves, on average, an 11% raise in 2008 for a total compensation of $2 million per company, according to preliminary data from the Corporate Library on Wednesday. Median total compensation for each director is now just under $200,000 a year, the independent research firm said. "Directors in the S&P 500 have a clear differential, earning almost twice the overall figure for total compensation at the median," the Corporate Library said. "They also earn higher median option awards and stock awards."

Only registered users can write comments.
Please login or register.

---